Search is Powered by Google
Cancer / Oncology News

Successful OCT Imaging Of Oral Cancer Tissue Announced By MDL And UCH, UK

Main Category: Cancer / Oncology
Also Included In: MRI / PET / Ultrasound;  Radiology / Nuclear Medicine
Article Date: 17 Jan 2008 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 stars

3.67 (3 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

Optical imaging company Michelson Diagnostics Ltd (MDL) announced successful initial results from clinical testing, on oral cancer tissue, of its groundbreaking OCT imaging technology by partner University College Hospital, London (UCH).

The tests, performed by UCH scientists on cancerous and suspected cancerous human oral issue, were designed to establish the potential for MDL's optical imaging technology to revolutionize head and neck cancer diagnosis and treatment. The tests involved comparing images taken by the MDL scanner of the tissue samples, with histopathology images analyzed by trained pathologists.

"We are very excited about the breakthrough in image quality that this system offers," said Mr Colin Hopper, Senior Maxillofacial Surgeon at UCH. He added "OCT could revolutionise the surveillance of pre-cancers in the mouth and eliminate the waiting time for biopsy results. It should also minimize surgery through improved disease mapping. This will provide cost effective treatments with improved cure rates".

In the tests, 25 oral tissue samples were collected from 14 patients of the UCH National Medical Laser Centre. The samples were scanned with the MDL OCT imaging system and then prepared for analysis by Pathologist Dr Brendan Conn. Clinical Research Fellow Mr Waseem Jerjes said "the histopathology results showed that it is possible to identify surface structures such as keratin and epithelial layers, the epidermal / dermal junction and areas of cellular crowding as well as any pathological changes that occurs at that level; this is very exciting, this method seems to hold great promises for early in vivo tumour diagnosis".

The company's highly innovative optical probe technology offers the best available sub-surface OCT images for research applications in cancer surgery guidance, surveillance and diagnosis.

Michelson Diagnostics Ltd is the UK's leading independent manufacturer and developer of Optical Coherence Tomography medical imaging equipment. Founded in 2006, it is based in SE London, UK. The company's highly innovative optical probe technology offers the best available sub-surface OCT images for cancer surgery guidance, surveillance and diagnostic applications.

http://www.michelsondiagnostics.co.uk




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...